Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
41152984 (PubMed )
Supplement: 13073_2025_1564_MOESM2_ESM.xlsx › Table_S6
Targeting c-Met in breast cancer: From mechanisms of chemoresistance to novel therapeutic strategies.
Iweala EEJ et al.
Current Research in Pharmacology and Drug Discovery, 2024
Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance.
Bahcall M et al.
Molecular Cancer Therapeutics, 2022
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.
Engstrom LD et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2017
A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.
Tiedt R et al.
Cancer Research, 2011
21697284 (PubMed )
Supplement: 00085472can104433-sup-f2_t4_meth.pdf
Select a paper to view details